Skip to main content
. 2020 Sep 7;91(3):e2020008. doi: 10.23750/abm.v91i3.10217

Table 2.

Characteristics of studies included in the lymphopenia mortality analysis cohort

Study Country & City Sample Size Cut-off (x10*9/l) Survivors Non-survivors
n (%) Age (yrs)* Women (%) Lymphopenia
n (%)
n (%) Age (yrs)* Women (%) Lymphopenia
n (%)
Zhou F et al., [26] Wuhan, China 191 0.8 137 (71.7%) 52 (45-58) 56 (41%) 36 (26.3%) 54 (28.3%) 69 (63-76) 16 (30%) 41 (75.9%)
Chen T et al., [27] Wuhan, Chins 274 0.5 161 (58.8%) 51 (37-66) 73 (45%) 8 (5%) 113 (41.2%) 68 (62-77) 30 (27%) 44 (40%)
0.8 161 (58.8%) 51 (37-66) 73 (45%) 48 (29.8%) 113 (41.2%) 68 (62-77) 30 (27%) 87 (78%)
1 161 (58.8%) 51 (37-66) 73 (45%) 76 (47.2%) 113 (41.2%) 68 (62-77) 30 (27%) 103 (91.2%)
Fan et al., [28] Wuhan, China 155 1.1 54 (34.8%) - - 47 (87.0%) 101 (65.2%) 65.5±9.74 37 (37%) 94 (93.1%)
Yao et al., [22] Dabieshan, China 108 0.8 12 (11.1%) - - 5 (41.7%) 96 (88.9%) 65.0
(51.0,73.5)
5 (41%) 18 (18.75%)
Bonetti et al., [29] Valcamonica, Italy 144 0.5 74 (51.4%) 62.1 (53-72.8) 24 (31.1%) 1 (1.4%) 70 (48.6%) 78 (64.2-84) 25 (35.7%) 13 (18.6%)
0.8 74 (51.4%) 62.1 (53-72.8) 24 (31.1%) 17 (23%) 70 (48.6%) 78 (64.2-84) 25 (35.7%) 28 (40%)
1.1 74 (51.4%) 62.1 (53-72.8) 24 (31.1%) 22 (29.7%) 70 (48.6%) 78 (64.2-84) 25 (35.7%) 15 (21.4%)